semaglutide causing thyroid cancer No Increased Risk for in Diabetic Patients Prescribed GLP-1 Medications Compared to Those Prescribed Insulin Increased GLP-1 Thyroid Cancer Risks

Beyond semaglutide, other innovative GLP-1 receptor agonist medications, such as Tirzepatide , which is also a GIP receptor agonist, are available and FDA-approved for once-weekly administration under brand names like Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management)

Combining Wegovy with other blood sugar-lowering drugs increases the risk of hypoglycemia

In contrast, the occurrence of vomiting and diarrhea did not show significant differences between the two groups

Fatigue Some fatigue during the first two months is common and reflects the rapid metabolic changes occurring

These symptoms occur most frequently during treatment initiation and dose escalation phases, typically diminishing in intensity as patients develop tolerance

Kanda, R